Clinical evaluation of ceftazidime in internal medicine in Japan.
A total of 424 medical patients were treated with ceftazidime: 376 were assessable for clinical efficacy and 413 for possible adverse events. The overall clinical efficacy rate was 80%. The eradication rates of initial pathogens were 82% in monomicrobial infections and 71% in polymicrobial infections. Adverse events considered to be attributable to ceftazidime were observed in 15 (3.6%) of the patients. Drug-related changes in laboratory parameters occurred in 29 patients but were always mild and transient. Ceftazidime appears to be a safe, efficacious antibiotic for treatment of infections in internal medicine.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D007564:Japan; D008111:Liver Function Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002442:Ceftazidime